Metsera CEO Whit Bernard shares an update on the company's obesity programs, and comments on the state of the field post ADA episode artwork

EPISODE · Jul 22, 2025 · 17 MIN

Metsera CEO Whit Bernard shares an update on the company's obesity programs, and comments on the state of the field post ADA

from BiotechTV - News · host BiotechTV

He describes data that Mestera presented at ADA for its monthly-dosed GLP1 and also its amylin analog. Plus, recent learnings about the field in general, including what orforglipron might mean for the oral therapy space and why Metsera believes in an oral peptide.

He describes data that Mestera presented at ADA for its monthly-dosed GLP1 and also its amylin analog. Plus, recent learnings about the field in general, including what orforglipron might mean for the oral therapy space and why Metsera believes in an oral peptide.

NOW PLAYING

Metsera CEO Whit Bernard shares an update on the company's obesity programs, and comments on the state of the field post ADA

0:00 17:46

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 17 minutes long.

When was this BiotechTV - News episode published?

This episode was published on July 22, 2025.

What is this episode about?

He describes data that Mestera presented at ADA for its monthly-dosed GLP1 and also its amylin analog. Plus, recent learnings about the field in general, including what orforglipron might mean for the oral therapy space and why Metsera believes in...

Can I download this BiotechTV - News episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!